Gp/642

THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT: Rosenblum, M.

February 19, 1998 FILED:

SERIAL NO.: 09/026,882

FOR: Immunotoxins Directed Against

CD33 Related Surface Antigens

Assistant Commissioner for Patents **BOX NON-FEE AMENDMENT** Washington, D.C. 20231

ART UNIT:

EXAMINER:

Eyler, Y.

DOCKET:

D5442C/CJP

RESPONSE TO RESTRICTION REQUIREMENT AND CERTIFICATE OF MAILING UNDER 37 CFR 1.8

Dear Sir:

In response to a Restriction Requirement mailed September 24, 1999 for the above-referenced patent application, Applicants hereby elect Group I, claims 8-15, drawn to methods of treating neoplasia or neoplastic cells comprising administering immunotoxin, without traverse.

certify 37 CFR 1.8 that I hereby under correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to Commissioner of Patents and Trademarks, Box Non-Fee Amendment, Washington DC 20231. Please return the enclosed postcard acknowledging receipt of this correspondence.

Respectfully submitted,

McGREGOR & ADLER, LLP 8011 Candle Lane

Houston, Texas 77071 (713) 777-2321

BAADLER@flash.net

Benjamin Aaron Adler, Ph.D., J.D.

Registration No. 35,423 Counsel for Applicant